UNC Lineberger Comprehensive Cancer Center 
Welcome,         Profile    Billing    Logout  
 7 Products   0 Diseases  7 Products   21 Trials   115 News 
20 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT06090864: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting
1/2
31
US
Chemotherapy, Cell infusion
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Relapse, Refractory
07/26
07/31
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
CERTAIN, NCT04526834: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruiting
1
21
US
CD30.CAR-T, CD30-directed genetically modified autologous T cells
Tessa Therapeutics
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
11/22
03/36
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
1
60
US
CAR T Cells, CD30.CAR T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
04/26
02/40
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, Stand Up To Cancer, National Cancer Institute (NCI)
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT03914885: Compassionate Use Re-Infusion of ATLCAR.CD30

No Longer Available
N/A
US
ATLCAR.CD30, CD30 CAR T cells, Bendamustine, Bendeka, Treanda, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
 
 
PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
PANDA-VAC, NCT04266730: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Not yet recruiting
1
6
US
PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine, Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
06/26
06/33
iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting
1
18
US
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, National Cancer Institute (NCI)
Neuroblastoma, Osteosarcoma
05/25
06/39
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
11/27
10/29
CAR.B7-H3 T / UNC Lineberger Comprehensive Cancer Center
NCT06347068: Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Recruiting
1
42
US
iC9-CAR.B7-H3 T Cell Therapy, iC9-CAR.B7-H3 T cells, cyclophosphamide, Cytoxan, fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI), M.D. Anderson Cancer Center
Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
05/26
05/28
NCT06158139: Autologous CAR-T Cells Targeting B7-H3 in PDAC

Recruiting
1
27
US
iC9-CAR.B7-H3 T cell infusion, Cellular Therapy
UNC Lineberger Comprehensive Cancer Center, M.D. Anderson Cancer Center
Pancreas Cancer, Relapse, Resistant Cancer
06/26
06/28
NCT06305299: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting
1
27
US
iC9-CAR.B7-H3 T cells, iC9-CAR.B7-H3 T, Cyclophosphamide, Cycloblastin, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
03/26
03/26
NCT05366179: Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Recruiting
1
36
US
CAR.B7-H3T cells infusion
UNC Lineberger Comprehensive Cancer Center
Glioblastoma Multiforme
05/30
05/30
NCT04670068: Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Active, not recruiting
1
7
US
CAR.B7-H3, Chimeric antigen receptor T cells with B7.H3 molecular target, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Epithelial Ovarian Cancer
12/24
02/30
ATLCAR.CD138 / UNC Lineberger Comprehensive Cancer Center
NCT03672318: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
25
US
CAR138 T Cells, ATLCAR.CD138, CAR.CD138 T cells
UNC Lineberger Comprehensive Cancer Center, Baylor College of Medicine, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Multiple Myeloma, Immune System Diseases
10/24
08/39
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
TT11 / Tessa Therap, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute
CHARIOT, NCT04268706: Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma

Active, not recruiting
2
97
US
CD30.CAR-T, Fludarabine, Fludara, Bendamustine, Bendeka
Tessa Therapeutics
Hodgkin Lymphoma, Adult, Hodgkin Disease Recurrent, Hodgkin Disease Refractory, Hodgkin Disease, Pediatric
05/25
03/37
NCT05634785: CD30 CAR for CD30+ NSGCT

Recruiting
2
18
US
ATLCAR.CD30 Cells, CAR.CD30 T cells, Cyclophosphamid, Cytoxan, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
12/26
12/26
NCT04083495: CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Recruiting
2
20
US
ATLCAR.CD30 T cells, Bendamustine, Bendeka, Fludarabine, Cyclophosphamide
UNC Lineberger Comprehensive Cancer Center
Peripheral T Cell Lymphoma
02/28
08/38
NCT02690545: Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Recruiting
1/2
40
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center
Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
09/27
08/38
NCT06090864: ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells

Recruiting
1/2
31
US
Chemotherapy, Cell infusion
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Relapse, Refractory
07/26
07/31
ACTION, NCT05352828: Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

Active, not recruiting
1b
15
US
Nivolumab, Opdivo, Autologous CD30.CAR-T, CD30-directed CAR-T cells, Fludarabine, Fludara, Bendamustine, Bendeka, Treanda
Tessa Therapeutics, Bristol-Myers Squibb
Classical Hodgkin Lymphoma, Hodgkin Disease Refractory, Hodgkin Disease Recurrent
12/25
12/37
NCT02663297: Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Active, not recruiting
1
18
US
ATLCAR.CD30 cells, CAR.CD30 T cells
UNC Lineberger Comprehensive Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type
01/21
01/37
CERTAIN, NCT04526834: Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma

Active, not recruiting
1
21
US
CD30.CAR-T, CD30-directed genetically modified autologous T cells
Tessa Therapeutics
Anaplastic Large Cell Lymphoma, Peripheral T Cell Lymphoma, Extranodal NK/T-cell Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
11/22
03/36
NCT02917083: CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

Recruiting
1
60
US
CAR T Cells, CD30.CAR T Cells
Baylor College of Medicine, The Methodist Hospital Research Institute
Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
04/26
02/40
LCCC 1606-ATL, NCT03602157: Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Recruiting
1
59
US
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine, Fludarabine
UNC Lineberger Comprehensive Cancer Center, Stand Up To Cancer, National Cancer Institute (NCI)
Lymphoma, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoproliferative Disorders, Neoplasms, Cutaneous Lymphoma, Cutaneous Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphomatoid Papulosis, Cutaneous T Cell Lymphoma, Gray Zone Lymphoma
09/26
09/41
NCT03914885: Compassionate Use Re-Infusion of ATLCAR.CD30

No Longer Available
N/A
US
ATLCAR.CD30, CD30 CAR T cells, Bendamustine, Bendeka, Treanda, Fludarabine, Fludara
UNC Lineberger Comprehensive Cancer Center
Hodgkin Lymphoma, Adult
 
 
PANDA-VAC / UNC Lineberger Comprehensive Cancer Center
PANDA-VAC, NCT04266730: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab

Not yet recruiting
1
6
US
PANDA-VAC, Personalized and adaptive neoantigen dose-adjusted vaccine, Pembrolizumab
UNC Lineberger Comprehensive Cancer Center
Squamous Cell Lung Cancer, Squamous Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
06/26
06/33
iC9.GD2.CAR.IL-15 T-cells / UNC Lineberger Comprehensive Cancer Center
NCT03721068: Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

Recruiting
1
18
US
iC9.GD2.CAR.IL-15 T-cells, Cyclophosphamide, Fludarabine
UNC Lineberger Comprehensive Cancer Center, United States Department of Defense, Bellicum Pharmaceuticals, National Cancer Institute (NCI)
Neuroblastoma, Osteosarcoma
05/25
06/39
NCT05620342: Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer

Recruiting
1
24
US
iC9.GD2.CAR.IL-15 T Infusion
UNC Lineberger Comprehensive Cancer Center, Bellicum Pharmaceuticals, United States Department of Defense
Lung Cancer, Small Cell Lung Carcinoma, Non Small Cell Lung Cancer
11/27
10/29
CAR.B7-H3 T / UNC Lineberger Comprehensive Cancer Center
NCT06347068: Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

Recruiting
1
42
US
iC9-CAR.B7-H3 T Cell Therapy, iC9-CAR.B7-H3 T cells, cyclophosphamide, Cytoxan, fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center, National Cancer Institute (NCI), M.D. Anderson Cancer Center
Breast Cancer, Relapse, Resistant Cancer, Triple Negative Breast Cancer
05/26
05/28
NCT06158139: Autologous CAR-T Cells Targeting B7-H3 in PDAC

Recruiting
1
27
US
iC9-CAR.B7-H3 T cell infusion, Cellular Therapy
UNC Lineberger Comprehensive Cancer Center, M.D. Anderson Cancer Center
Pancreas Cancer, Relapse, Resistant Cancer
06/26
06/28
NCT06305299: Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells

Recruiting
1
27
US
iC9-CAR.B7-H3 T cells, iC9-CAR.B7-H3 T, Cyclophosphamide, Cycloblastin, Endoxan, Neosar, Procytox, Revimmune, Fludarabine, Fludara, Fludarabine Phosphate
UNC Lineberger Comprehensive Cancer Center
Ovary Neoplasm, Ovarian Cancer, Epithelial Ovarian Cancer, Recurrent
03/26
03/26
NCT05366179: Autologous CAR-T Cells Targeting B7-H3 in Recurrent or Refractory GBM CAR.B7-H3Tc

Recruiting
1
36
US
CAR.B7-H3T cells infusion
UNC Lineberger Comprehensive Cancer Center
Glioblastoma Multiforme
05/30
05/30
NCT04670068: Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian

Active, not recruiting
1
7
US
CAR.B7-H3, Chimeric antigen receptor T cells with B7.H3 molecular target, Fludarabine, FLUDARA, Cyclophosphamide, Cytoxan
UNC Lineberger Comprehensive Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
Epithelial Ovarian Cancer
12/24
02/30
ATLCAR.CD138 / UNC Lineberger Comprehensive Cancer Center
NCT03672318: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
25
US
CAR138 T Cells, ATLCAR.CD138, CAR.CD138 T cells
UNC Lineberger Comprehensive Cancer Center, Baylor College of Medicine, University Cancer Research Fund at Lineberger Comprehensive Cancer Center
Multiple Myeloma, Immune System Diseases
10/24
08/39

Download Options